Prot #GS-US-312-0116: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia

Project: Research project

Project Details

StatusFinished
Effective start/end date9/28/129/28/15

Funding

  • PPD Development (Prot #GS-US-312-0116)
  • Gilead Sciences, Inc. (Prot #GS-US-312-0116)